Jiangsu Hengrui Medicine Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jiangsu Hengrui Medicine Co., Ltd.
After Novartis, US firm Coherus leaps into the China immuno-oncology fray by licensing rights to innovative drugs from Shanghai's Junshi.
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.
BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.
- Generic Drugs
- Radiopharmaceuticals, Contrast Agents
- Large Molecule
- Other Names / Subsidiaries
- Hengrui Therapeutics, Inc.